论文部分内容阅读
新蒽环类抗生素Idarubicin和Epirub—icin保留抗肿瘤活性,毒性较低。但在治疗中发现Idarubicin对心脏有毒性。病人给予Idarubicin12mg/m~2静注2d和阿糖胞苷400mg/m~2连续静滴5d,在21d后如未达到消除骨髓中白血胚细胞作用,则进行第2次相同的治疗。在病人白血病缓解后,给予相同疗程进行巩固治疗,再以阿糖胞苷每日1g/m~2连续静滴5d、在治疗中至少有50%剂量用于诱导缓解治疗,但巩固治疗剂量相
New anthracycline antibiotics Idarubicin and Epirub-icin retain anti-tumor activity with low toxicity. However, Idarubicin was found to be toxic to the heart during treatment. Patients were given intravenous Idarubicin 12mg / m 2 intravenous infusion 2d and cytarabine 400mg / m 2 continuous intravenous infusion of 5d, 21d after the bone marrow if not achieve the elimination of the role of white blood cells, the second treatment the same. In patients with leukemia remission, given the same course of treatment to consolidate treatment, and then cytarabine daily intravenous infusion of 1g / m ~ 2 5d, at least 50% of the dose used to induce remission therapy, but to consolidate the therapeutic dose phase